SOURCE: Theravance, Inc.

Theravance, Inc.

April 20, 2011 16:05 ET

Theravance to Webcast 2011 Annual Meeting of Stockholders on April 27, 2011

SOUTH SAN FRANCISCO, CA--(Marketwire - Apr 20, 2011) - Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its 2011 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Wednesday, April 27, 2011.

An accompanying listen-only conference call will be held at 4:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the audio feed live via the internet may do so by visiting the company's web site at www.theravance.com. To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the 2011 Annual Meeting of Stockholders will be available on the company's web site for 30 days through May 27, 2011. A telephone replay will also be available through 11:59 p.m. Eastern Daylight Time on May 4, 2011 by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering confirmation code 54413580.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: the RELOVAIR™ program, the LAMA/LABA ('719/vilanterol (VI)) program and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, each with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist (PµMA) program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at www.theravance.com.

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

RELOVAIR™ is a trademark of GlaxoSmithKline group of companies.

Contact Information

  • Contact Information:
    Michael W. Aguiar
    Senior Vice President
    and Chief Financial Officer
    650-808-4100
    Email Contact